ZGNX Zogenix Inc.

23.1
-1.63  -7%
Previous Close 24.73
Open 23.8
Price To Book 5.2
Market Cap 1,274,571,283
Shares 55,176,246
Volume 735,028
Short Ratio
Av. Daily Volume 1,446,517
Stock charts supplied by TradingView

NewsSee all news

  1. Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    EMERYVILLE, Calif., March 06, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it has closed its previously announced

  2. Zogenix Prices Public Offering of Common Stock

    EMERYVILLE, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it has priced an underwritten public offering

  3. Zogenix Announces Proposed Public Offering of Common Stock

    EMERYVILLE, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it intends to offer and sell, subject to

  4. Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results

    NDA for FINTEPLA® in Dravet syndrome accepted for review by FDA; new PDUFA target acion date of June 25, 2020Two-year interim analysis of FINTEPLA open-label extension study in Dravet syndrome patients demonstrated a 77%

  5. Zogenix Announces FDA Extension of Review Period for FINTEPLA® in Dravet Syndrome

    EMERYVILLE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data met primary endpoint with high dose, low dose secondary endpoint not met - February 6, 2020.
ZX008 - (Study 1601)
Lennox-Gastaut syndrome
Approved July 16, 2009.
Sumavel
Migraine
Approved October 25, 2013.
Zohydro ER
Moderate to severe pain
PDUFA date under priority review extended by three months to June 25, 2020
FINTEPLA (ZX008)
Dravet syndrom
Approved January 30, 2015.
Abuse deterrent formulations of Zohydro ER
Moderate to severe pain

Latest News

  1. Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    EMERYVILLE, Calif., March 06, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it has closed its previously announced

  2. Zogenix Prices Public Offering of Common Stock

    EMERYVILLE, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it has priced an underwritten public offering

  3. Zogenix Announces Proposed Public Offering of Common Stock

    EMERYVILLE, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it intends to offer and sell, subject to

  4. Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results

    NDA for FINTEPLA® in Dravet syndrome accepted for review by FDA; new PDUFA target acion date of June 25, 2020Two-year interim analysis of FINTEPLA open-label extension study in Dravet syndrome patients demonstrated a 77%

  5. Zogenix Announces FDA Extension of Review Period for FINTEPLA® in Dravet Syndrome

    EMERYVILLE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has

  6. Zogenix to Release Fourth Quarter and Full-Year 2019 Financial Results and Host Conference Call and Webcast on March 2

    EMERYVILLE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the

  7. Zogenix Announces Positive Top-line Results from Global Pivotal Phase 3 Trial of FINTEPLA® for the Treatment of Lennox-Gastaut Syndrome

    Primary Endpoint Achieved - Statistically Significant Reduction in Drop Seizures for FINTEPLA 0.7 mg/kg/day versus Placebo FINTEPLA Also Demonstrated Statistically Significant Improvement on Multiple Secondary Endpoints

  8. The Lancet Publishes Phase 3 Trial Results for Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome

    FINTEPLA as adjunctive therapy showed a significant, dose-dependent reduction in convulsive seizure frequency in Dravet syndrome patients versus placebo EMERYVILLE, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Zogenix,

  9. Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2019 Annual Meeting

    EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will host an Investor Update Lunch on its

  10. JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens

    Addition of FINTEPLA to stiripentol-inclusive regimens provided a 54% greater reduction in study patients' mean monthly convulsive seizure frequency compared to placeboA significantly greater proportion of study patients

  11. Zogenix to Present New Data for Its Investigational Drug FINTEPLA® at the American Epilepsy Society Annual Meeting

    EMERYVILLE, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, announced that data from eight abstracts related to its

  12. Zogenix to Participate in the 31st Annual Piper Jaffray Healthcare Conference

    EMERYVILLE, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a

  13. Zogenix Announces FDA Acceptance for Filing of New Drug Application and Priority Review for FINTEPLA® for the Treatment of Dravet Syndrome

    EMERYVILLE, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has

  14. Zogenix to Present at Two Investor Conferences in November

    EMERYVILLE, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and

  15. Zogenix Provides Corporate Update and Reports Third Quarter 2019 Financial Results

    Resubmitted NDA for FINTEPLA® for the treatment of Dravet syndromeEnrollment completed for FINTEPLA global Phase 3 trial in Lennox Gastaut syndrome; top-line data anticipated in Q1 2020Acquired Modis Therapeutics, Inc.;

  16. Zogenix to Release Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7

    EMERYVILLE, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the

  17. Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA® in Dravet Syndrome

    Data have shown long-term, clinically meaningful convulsive seizure reduction (75.5%; p<0.001) in Dravet syndrome patients under 6 years old, as well as clinically meaningful and profound reduction in high-risk

  18. Zogenix Presents Positive Clinical Study Results for Investigational Treatment for TK2 Deficiency

    Safety and efficacy data from a global, retrospective Phase 2 study (RETRO) support potential for deoxynucleoside substrate enhancement therapy (SET) to treat TK2 deficiency, an often-fatal mitochondrial DNA depletion

  19. Zogenix Resubmits New Drug Application for FINTEPLA® for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration

    EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has resubmitted its New Drug Application

  20. Zogenix Completes Acquisition of Modis Therapeutics, Inc.

    EMERYVILLE, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has successfully completed its acquisition

  21. INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

  22. INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

  23. Zogenix Announces Acquisition of Modis Therapeutics, Inc.

    Advances Zogenix's strategy to provide transformative therapies to patients and families living with serious rare diseasesAdds MT1621, a proprietary, late-stage investigational medicine targeting Thymidine Kinase 2